Market research
BD1.AU BARD1 Life Sciences Limited
AU AUD Health Care Providers & Services
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 95M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.64
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Health Care Providers & Services
- Industry
- Healthcare
- ISIN
- AU000000BD12
- Market cap
- 95M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.64
About
About BARD1 Life Sciences Limited
BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia. The company offers hTERT test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for ovarian and breast cancers, and research-stage projects for prostate and other cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Research context
BARD1 Life Sciences Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Health Care Providers & Services
- Industry
- Healthcare
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BD1.AU discussion.
5 years, 6 months ago
BARD1 Life Sciences Limited is currently in a long term uptrend where the price is trading 6.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BARD1 Life Sciences Limited's total revenue rose by 298.0% to $182K since the same quarter in the previous year.
Its net income has dropped by 108.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 220.4% to $-2M since the same quarter in the previous year.
Based on the above factors, BARD1 Life Sciences Limited gets an overall score of 3/5.